Skip to main content
Top
Published in: BMC Cancer 1/2021

01-12-2021 | Obesity | Research article

Associations of specific-age and decade recall body mass index trajectories with obesity-related cancer

Authors: Charlotte Watson, Andrew G. Renehan, Nophar Geifman

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Excess body fatness, commonly approximated by a one-off determination of body mass index (BMI), is associated with increased risk of at least 13 cancers. Modelling of longitudinal BMI data may be more informative for incident cancer associations, e.g. using latent class trajectory modelling (LCTM) may offer advantages in capturing changes in patterns with time. Here, we evaluated the variation in cancer risk with LCTMs using specific age recall versus decade recall BMI.

Methods

We obtained BMI profiles for participants from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. We developed gender-specific LCTMs using recall data from specific ages 20 and 50 years (72,513 M; 74,837 W); decade data from 30s to 70s (42,113 M; 47,352 W) and a combination of both (74,106 M, 76,245 W). Using an established methodological framework, we tested 1:7 classes for linear, quadratic, cubic and natural spline shapes, and modelled associations for obesity-related cancer (ORC) incidence using LCTM class membership.

Results

Different models were selected depending on the data type used. In specific age recall trajectories, only the two heaviest classes were associated with increased risk of ORC. For the decade recall data, the shapes appeared skewed by outliers in the heavier classes but an increase in ORC risk was observed. In the combined models, at older ages the BMI values were more extreme.

Conclusions

Specific age recall models supported the existing literature changes in BMI over time are associated with increased ORC risk. Modelling of decade recall data might yield spurious associations.
Appendix
Available only for authorised users
Literature
3.
9.
go back to reference Song M, Hu FB, Wu K, Must A, Chan AT, Willett WC, et al. Trajectory of body shape in early and middle life and all cause and cause specific mortality: results from two prospective US cohort studies. BMJ. 2016;353:i2195.CrossRefPubMedPubMedCentral Song M, Hu FB, Wu K, Must A, Chan AT, Willett WC, et al. Trajectory of body shape in early and middle life and all cause and cause specific mortality: results from two prospective US cohort studies. BMJ. 2016;353:i2195.CrossRefPubMedPubMedCentral
11.
go back to reference Kelly SP, Graubard BI, Andreotti G, Younes N, Cleary SD, Cook MB. Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial. J Natl Cancer Inst. 2016;109(3):djw225. https://doi.org/10.1093/jnci/djw225. Kelly SP, Graubard BI, Andreotti G, Younes N, Cleary SD, Cook MB. Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial. J Natl Cancer Inst. 2016;109(3):djw225. https://​doi.​org/​10.​1093/​jnci/​djw225.
15.
go back to reference Black A, Huang WY, Wright P, Riley T, Mabie J, Mathew S, et al. PLCO: evolution of an epidemiologic resource and opportunities for future studies. Rev Recent Clin Trials. 2015;10(3):23845.CrossRef Black A, Huang WY, Wright P, Riley T, Mabie J, Mathew S, et al. PLCO: evolution of an epidemiologic resource and opportunities for future studies. Rev Recent Clin Trials. 2015;10(3):23845.CrossRef
16.
Metadata
Title
Associations of specific-age and decade recall body mass index trajectories with obesity-related cancer
Authors
Charlotte Watson
Andrew G. Renehan
Nophar Geifman
Publication date
01-12-2021
Publisher
BioMed Central
Keywords
Obesity
Obesity
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-08226-4

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine